NFL Biosciences further strengthens its operational team with the arrival of a Head of Development and Manufacturing

Successful capital increase with over €3 million raised

NFL Biosciences launches a fundraising round for 3 million euros through a capital increase

NFL Biosciences showcases the results of its studies to the scientific and pharmaceutical communities

2023 full-year business and earnings update

Initiation of analyst coverage by PORTZAMPARC – BNP PARIBAS GROUP

NFL Biosciences will present the results of the PRECESTO clinical study at the SRNT conference

Success of the study with the CEA

2024 Financial Calendar

PRE-IND application filed with the FDA in the United States for NFL-301, indicated for reducing alcohol consumption

NFL BIOSCIENCES, a company committed to the fight against tobacco smoking, presents its clinical devlopment advances to help smokers quit (french only)

2023 first-half business and earnings update

Promising results of the PRECESTO clinical trial revealing a prolonged effect for NFL-101 and modification of the strategy for communicating the CESTO II study results

Patent application filed in the United States for reducing alcohol consumption with NFL-301 & preparation of a pre-IND application submission with the FDA

Co-founder shareholder further strengthens his position by exercising “BSPCE” warrants

GB Holding takes a stake in the company’s capital upon the exercise of share subscription warrants

Results of the Combined General Meeting of June 27, 2023

Approval for its patent to be granted on NFL-101 in Europe and approval of the clinical development

Shareholder documentation for the Annual General Meeting (french only)

Recruitment completed for the PRECESTO study

Availability of the 2022 Annual Report (french only)

2022 full-year business and earnings update

Changes in the governance

Inclusion of the first volunteer in the PRECESTO study

NFL Biosciences receives €1.7 million in « Avance Innovation » funding from Bpifrance

Collaboration with the CEA to study the mechanism of action of its drug candidate NFL-101

Very successful capital increase for NFL Biosciences with over €3 million raised

NFL Biosciences launches a round of fundraising for approximately 2.5 million euros

NFL Biosciences takes part in the Société Francophone de Tabacologie congress (french only)

Clinical trial approved to demonstrate the complementarity of NFL-101 with other smoking cessation treatments

New patent application associating NFL-101 with other smoking cessation treatments

2022 first-half business and earnings

NFL Biosciences partners mith Themis Medicare for the development of NFL-101 in India

Participation in the first annual H.C.Wainwright Mental Health Conference (french only)

NFL Biosciences, committed to the fight against tobacco smoking, fully supports World No Tobacco Day on May 31st (french only)

Decision to approve the issuing of its patent in South Korea

Decision to approve the issuing of its patent in China

2021 full-year business and earnings

Co-development agreement for a drug candidate to reduce alcohol consumption

Phase II/III clinical trial launched for smoking cessation

Agreement signed with Diverchim to manufacture its active ingredients

2021 first-half business and earnings

Approval for its patent to be granted in the United States

Phase II/III clinical trial for NFL-101 for smokingcessation approved in France

Analyst coverage launched with Invest Securities

Implementation of a liquidity contract (french only)

NFL Biosciences successfully listed on Euronext Growth Paris (french only)

NFL Biosciences launches its Initial Public Offering on Euronext Growth Paris (french only)

French smoking cessation innovation approved for Phase II/III clinical trial (french only)